Trinity gains bioMerieux blood coagulation testing line
This article was originally published in The Gray Sheet
Automated instruments and reagent menu for blood clotting parameter analysis composing bioMerieux's hemostasis product line are acquired by diagnostics firm Trinity Biotech May 25. Trinity will pay up to $51.9 mil., including $40 mil. at closing, with deferred payments of up to $11.9 mil. over two years. Combining the bioMerieux line with Trinity's existing coagulation testing products will add $40 mil. to Trinity's revenue next year and boost its share of the $600 mil. worldwide coagulation testing market from its current 5% level to an estimated 13%, the firm says. The market is growing at about 5% annually. The deal is in line with bioMerieux' focus on infectious diseases, cancer and cardiovascular diseases...
You may also be interested in...
BioMérieux announced two deals last week as part of its five-year strategic plan focusing on infectious diseases and personalized diagnostics
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.